Coherus Oncology, Inc. (CHRS) intrinsic value & 10-year financials
Coherus Oncology, Inc. (CHRS) has a Graham intrinsic value of $16.75 per share. At $0.99 on Oct 17, 2026, the stock trades 94% below that value. Over the last 10 fiscal years revenue shrank 15.4% a year to $42.2M, with an average return on invested capital of -115.7%.
- Graham intrinsic value
- $16.75
- Share price (Oct 17, 2026)
- $0.99
- Price vs Graham value
- 94% below
- Market cap
- $116.0M
- Revenue (FY2025)
- $42.2M
- Revenue growth (10-yr CAGR)
- -15.4%
- ROIC (10-yr avg)
- -115.7%
- Free cash flow (FY2025)
- —
CHRS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $42.2M | $168.0M | $1.43 | — | -429.5% | 128.9% |
| FY2024 | $267.0M | $28.5M | $0.25 | — | -41.8% | 40.9% |
| FY2023 | $257.2M | -$237.9M | -$2.53 | -$175.2M | -79.0% | 83.3% |
| FY2022 | $211.0M | -$291.8M | -$3.76 | -$243.2M | -121.7% | 101.1% |
| FY2021 | $326.6M | -$287.1M | -$3.81 | -$38.7M | -80.8% | 93.8% |
| FY2020 | $475.8M | $132.2M | $1.62 | $146.9M | 32.9% | -127.6% |
| FY2019 | $356.1M | $89.8M | $1.23 | $26.5M | 30.3% | -209.8% |
| FY2018 | $0 | -$209.3M | -$3.22 | -$160.1M | — | 184.2% |
| FY2017 | $1.6M | -$238.2M | -$4.48 | -$204.9M | -14918.8% | -886.8% |
| FY2016 | $189.5M | -$127.3M | — | -$259.1M | -61.2% | -564.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Coherus Oncology, Inc. is facing top-line stagnation, with revenue contracting over the decade.
Coherus Oncology, Inc. has earned high returns on invested capital, averaging 40.0% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Coherus Oncology, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Coherus Oncology, Inc. is modeled at 2.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $16.75 per share.